163 related articles for article (PubMed ID: 7805359)
1. Antifungal activity of a new triazole, D0870, compared with four other antifungal agents tested against clinical isolates of Candida and Torulopsis glabrata.
Pfaller MA; Bale MJ; Buschelman B; Rhomberg P
Diagn Microbiol Infect Dis; 1994 Jun; 19(2):75-80. PubMed ID: 7805359
[TBL] [Abstract][Full Text] [Related]
2. Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae.
Pfaller MA; Messer S; Jones RN
Antimicrob Agents Chemother; 1997 Feb; 41(2):233-5. PubMed ID: 9021172
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of D0870 compared with those of other azoles against fluconazole-resistant Candida spp.
Wardle HM; Law D; Moore CB; Mason C; Denning DW
Antimicrob Agents Chemother; 1995 Apr; 39(4):868-71. PubMed ID: 7785986
[TBL] [Abstract][Full Text] [Related]
4. Variations in DNA subtype and antifungal susceptibility among clinical isolates of Candida tropicalis.
Zhang J; Hollis RJ; Pfaller MA
Diagn Microbiol Infect Dis; 1997 Mar; 27(3):63-7. PubMed ID: 9147006
[TBL] [Abstract][Full Text] [Related]
5. In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp.
Marco F; Pfaller MA; Messer S; Jones RN
Antimicrob Agents Chemother; 1998 Jan; 42(1):161-3. PubMed ID: 9449278
[TBL] [Abstract][Full Text] [Related]
6. [Antifungal activities of D0870 against fluconazole-resistant Candida albicans].
Kojima M; Yamada H; Nakamura S; Kikuchi M; Nakanishii T; Takahashi Y; Mochizuki H; Mikami Y
Nihon Ishinkin Gakkai Zasshi; 1999; 40(4):209-15. PubMed ID: 10536307
[TBL] [Abstract][Full Text] [Related]
7. Colorimetric MTT assessment of antifungal activity of D0870 against fluconazole-resistant Candida albicans.
Yang HC; Mikami Y; Yazawa K; Taguchi H; Nishimura K; Miyaji M; Branchini ML; Aoki FH; Yamamoto K
Mycoses; 1998 Dec; 41(11-12):477-80. PubMed ID: 9919890
[TBL] [Abstract][Full Text] [Related]
8. In vitro antifungal activity of BMS-207147 and itraconazole against yeast strains that are non-susceptible to fluconazole.
Fung-Tomc JC; White TC; Minassian B; Huczko E; Bonner DP
Diagn Microbiol Infect Dis; 1999 Oct; 35(2):163-7. PubMed ID: 10579098
[TBL] [Abstract][Full Text] [Related]
9. In-vitro activity of D0870, a new triazole antifungal drug, in comparison with fluconazole and itraconazole against Aspergillus fumigatus and Candida krusei.
Venkateswarlu K; Denning DW; Kelly SL
J Antimicrob Chemother; 1997 Jun; 39(6):731-6. PubMed ID: 9222042
[TBL] [Abstract][Full Text] [Related]
10. In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans.
Pfaller MA; Messer SA; Hollis RJ; Jones RN
Antimicrob Agents Chemother; 2001 Oct; 45(10):2862-4. PubMed ID: 11557481
[TBL] [Abstract][Full Text] [Related]
11. Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp.
Marco F; Pfaller MA; Messer SA; Jones RN
Diagn Microbiol Infect Dis; 1998 Sep; 32(1):33-7. PubMed ID: 9791755
[TBL] [Abstract][Full Text] [Related]
12. In-vitro comparative activity of UR-9825, itraconazole and fluconazole against clinical isolates of Candida spp.
Ramos G; Cuenca-Estrella M; Monzón A; Rodríguez-Tudela JL
J Antimicrob Chemother; 1999 Aug; 44(2):283-6. PubMed ID: 10473237
[TBL] [Abstract][Full Text] [Related]
13. Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B.
Cuenca-Estrella M; Mellado E; Díaz-Guerra TM; Monzón A; Rodríguez-Tudela JL
J Antimicrob Chemother; 2000 Sep; 46(3):475-7. PubMed ID: 10980178
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of voriconazole against Candida species.
Kauffman CA; Zarins LT
Diagn Microbiol Infect Dis; 1998 May; 31(1):297-300. PubMed ID: 9597390
[TBL] [Abstract][Full Text] [Related]
15. In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole.
Pfaller MA; Messer SA; Hollis RJ; Jones RN; Doern GV; Brandt ME; Hajjeh RA
Antimicrob Agents Chemother; 1998 Dec; 42(12):3242-4. PubMed ID: 9835520
[TBL] [Abstract][Full Text] [Related]
16. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
[TBL] [Abstract][Full Text] [Related]
17. In vitro susceptibilities of clinical yeast isolates to three antifungal agents determined by the microdilution method.
Pfaller MA; Barry AL
Mycopathologia; 1995; 130(1):3-9. PubMed ID: 7666925
[TBL] [Abstract][Full Text] [Related]
18. In vitro activities of voriconazole (UK-109, 496), fluconazole, itraconazole and amphotericin B against 132 non-albicans bloodstream yeast isolates (CANARI study).
Swinne D; Watelle M; Van der Flaes M; Nolard N
Mycoses; 2004 Jun; 47(5-6):177-83. PubMed ID: 15189180
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum.
Hata K; Kimura J; Miki H; Toyosawa T; Nakamura T; Katsu K
Antimicrob Agents Chemother; 1996 Oct; 40(10):2237-42. PubMed ID: 8891121
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of a new antifungal triazole, D0870, against Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus.
Barchiesi F; Colombo AL; McGough DA; Fothergill AW; Rinaldi MG
Antimicrob Agents Chemother; 1994 Nov; 38(11):2553-6. PubMed ID: 7872746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
